Name: UMIN ID:
Unique ID issued by UMIN | UMIN000005569 |
---|---|
Receipt number | R000005889 |
Scientific Title | Phase II study of maintenance Bevacizumab with Pemetrexed after induction therapy of Cisplatin, Pemetrexed, and Bevacizumab in patients with advanced non-squamous non-small-cell lung cancer |
Date of disclosure of the study information | 2011/05/08 |
Last modified on | 2019/07/29 11:58:25 |
No. | Disposal | Last modified on | Item of update | |
---|---|---|---|---|
1 | Insert | 2011/05/08 09:56:52 | ||
2 | Update | 2014/01/10 12:18:57 | Email Address Address TEL Post marketing survey by drug manufacture etc., specified by Japanese law. |
|
3 | Update | 2017/04/04 16:28:59 | Control |
|
4 | Update | 2017/04/04 16:29:55 | Name of primary person or sponsor Institute Organization Organization |
|
5 | Update | 2017/04/04 16:30:15 | Recruitment status |
|
6 | Update | 2019/07/29 11:21:27 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address Address TEL Last name of contact person Last name of contact person Zip code Address Address TEL Organization Organization Organization Address Address Tel |
|
7 | Update | 2019/07/29 11:51:30 | Recruitment status Date of IRB Anticipated trial start date Last follow-up date Date of closure to data entry Date trial data considered complete Date analysis concluded |
|
8 | Update | 2019/07/29 11:53:38 | URL releasing protocol Publication of results URL related to results and publications Number of participants that the trial has enrolled Results Results Results date posted Baseline Characteristics Baseline Characteristics Participant flow Participant flow Adverse events Adverse events Outcome measures Outcome measures |
|
9 | Update | 2019/07/29 11:58:25 | URL related to results and publications |